<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Swedish Orphan Biovitrum Ab (publ) — News on 6ix</title>
<link>https://6ix.com/company/swedish-orphan-biovitrum-ab-publ</link>
<description>Latest news and press releases for Swedish Orphan Biovitrum Ab (publ) on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Thu, 09 Apr 2026 20:21:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/swedish-orphan-biovitrum-ab-publ" rel="self" type="application/rss+xml" />
<item>
<title>Sobi Receives Health Canada Approval for EMPAVELI® (pegcetacoplan) for the Treatment of C3G and Primary IC-MPGN</title>
<link>https://6ix.com/company/swedish-orphan-biovitrum-ab-publ/news/sobi-receives-health-canada-approval-for-empavelir-pegcetacoplan-for-the-treatment-of-c3g-and-primary-ic-mpgn</link>
<guid isPermaLink="true">https://6ix.com/company/swedish-orphan-biovitrum-ab-publ/news/sobi-receives-health-canada-approval-for-empavelir-pegcetacoplan-for-the-treatment-of-c3g-and-primary-ic-mpgn</guid>
<pubDate>Thu, 09 Apr 2026 20:21:00 GMT</pubDate>
<description>EMPAVELI® (pegcetacoplan) is the first approved treatment for C3G or primary IC-MPGN for patients 12 years and older in Canada Approval supported by Phase 3 52-week VALIANT study demonstrated reduced proteinuria, stabilized kidney function and C3 deposit clearance WALTHAM, Mass., April 09, 2026 (GLOBE NEWSWIRE) -- Swedish Orphan Biovitrum AB (publ) (Sobi™) (STO:SOBI) announced today that Health Canada has approved EMPAVELI® (pegcetacoplan), a complement inhibitor, for the treatment of adult and</description>
</item>
<item>
<title>Sobi publishes Annual and Sustainability Report for 2025</title>
<link>https://6ix.com/company/swedish-orphan-biovitrum-ab-publ/news/sobi-publishes-annual-and-sustainability-report-for-2025</link>
<guid isPermaLink="true">https://6ix.com/company/swedish-orphan-biovitrum-ab-publ/news/sobi-publishes-annual-and-sustainability-report-for-2025</guid>
<pubDate>Tue, 31 Mar 2026 11:03:00 GMT</pubDate>
<description>Swedish Orphan Biovitrum AB (publ) (Sobi®) today published its Annual and Sustainability report for 2025, outlining the company's progress in unlocking the potential of breakthrough innovations and therapies for people living with rare diseases.</description>
</item>
<item>
<title>Notice of Annual General Meeting in Swedish Orphan Biovitrum AB (publ)</title>
<link>https://6ix.com/company/swedish-orphan-biovitrum-ab-publ/news/notice-of-annual-general-meeting-in-swedish-orphan-biovitrum-ab-publ</link>
<guid isPermaLink="true">https://6ix.com/company/swedish-orphan-biovitrum-ab-publ/news/notice-of-annual-general-meeting-in-swedish-orphan-biovitrum-ab-publ</guid>
<pubDate>Fri, 27 Mar 2026 07:56:00 GMT</pubDate>
<description>The shareholders in Swedish Orphan Biovitrum AB (publ) (Sobi®) Reg. No. 556038-9321, are hereby summoned to the Annual General Meeting (the "Meeting"), to be held on Wednesday, 6 May 2026 at 10.00 at IVA Konferenscenter, Grev Turegatan 16, Stockholm, Sweden.</description>
</item>
<item>
<title>Sobi Capital Markets Day 2026: Bringing brilliant ideas to life and building the next chapter with ambition to deliver SEK 55bn by 2030</title>
<link>https://6ix.com/company/swedish-orphan-biovitrum-ab-publ/news/sobi-capital-markets-day-2026-bringing-brilliant-ideas-to-life-and-building-the-next-chapter-with-ambition-to-deliver-sek-55bn-by-2030</link>
<guid isPermaLink="true">https://6ix.com/company/swedish-orphan-biovitrum-ab-publ/news/sobi-capital-markets-day-2026-bringing-brilliant-ideas-to-life-and-building-the-next-chapter-with-ambition-to-deliver-sek-55bn-by-2030</guid>
<pubDate>Wed, 18 Feb 2026 07:36:00 GMT</pubDate>
<description>Sobi® (STO: SOBI) today hosts its Capital Markets Day, where senior management will provide an update on the company's strategy and outline its new mid-term outlook, aiming to achieve SEK 55bn revenue by 2030, while building a resilient platform for sustained growth beyond 2030. Sobi aims to have an adjusted EBITA margin in the upper 30s percentage of revenue by 2030.</description>
</item>
<item>
<title>Sobi to host a Capital Markets Day on 18 February 2026</title>
<link>https://6ix.com/company/swedish-orphan-biovitrum-ab-publ/news/sobi-to-host-a-capital-markets-day-on-18-february-2026</link>
<guid isPermaLink="true">https://6ix.com/company/swedish-orphan-biovitrum-ab-publ/news/sobi-to-host-a-capital-markets-day-on-18-february-2026</guid>
<pubDate>Wed, 11 Feb 2026 12:24:00 GMT</pubDate>
<description>Swedish Orphan Biovitrum AB (Sobi) invites investors, analysts, and other stakeholders to its upcoming Capital Markets Day (CMD), which will be held in person in Stockholm, Sweden, on 18 February 2026, starting at 13:00 CET. A live webcast will also be available for remote participants.</description>
</item>
<item>
<title>Sobi completes acquisition of Arthrosi Therapeutics, strengthening pipeline for the potential treatment of gout</title>
<link>https://6ix.com/company/swedish-orphan-biovitrum-ab-publ/news/sobi-completes-acquisition-of-arthrosi-therapeutics-strengthening-pipeline-for-the-potential-treatment-of-gout</link>
<guid isPermaLink="true">https://6ix.com/company/swedish-orphan-biovitrum-ab-publ/news/sobi-completes-acquisition-of-arthrosi-therapeutics-strengthening-pipeline-for-the-potential-treatment-of-gout</guid>
<pubDate>Mon, 09 Feb 2026 14:47:00 GMT</pubDate>
<description>Swedish Orphan Biovitrum AB (publ) Sobi® (STO: SOBI) and Arthrosi Therapeutics, Inc. (Arthrosi) announced today the completion of the acquisition of Arthrosi by Sobi.</description>
</item>
<item>
<title>Sobi Q4 and FY 2025 report: Closing the year with significant growth and strategic progress</title>
<link>https://6ix.com/company/swedish-orphan-biovitrum-ab-publ/news/sobi-q4-and-fy-2025-report-closing-the-year-with-significant-growth-and-strategic-progress</link>
<guid isPermaLink="true">https://6ix.com/company/swedish-orphan-biovitrum-ab-publ/news/sobi-q4-and-fy-2025-report-closing-the-year-with-significant-growth-and-strategic-progress</guid>
<pubDate>Thu, 05 Feb 2026 07:25:00 GMT</pubDate>
<description>Swedish Orphan Biovitrum AB (publ) (Sobi®) today announced its report for the fourth quarter and full year of 2025.</description>
</item>
<item>
<title>Sobi to Showcase Scientific advances and Commitment to the Haemophilia community at EAHAD 2026</title>
<link>https://6ix.com/company/swedish-orphan-biovitrum-ab-publ/news/sobi-to-showcase-scientific-advances-and-commitment-to-the-haemophilia-community-at-eahad-2026</link>
<guid isPermaLink="true">https://6ix.com/company/swedish-orphan-biovitrum-ab-publ/news/sobi-to-showcase-scientific-advances-and-commitment-to-the-haemophilia-community-at-eahad-2026</guid>
<pubDate>Tue, 03 Feb 2026 09:09:00 GMT</pubDate>
<description>Swedish Orphan Biovitrum AB (publ) (Sobi) (STO: SOBI) today announced its participation at the 19th Annual Congress of the European Association for Haemophilia and Allied Disorders (EAHAD), taking place 3-6 February 2026 in Dublin, Ireland. At this year's meeting, Sobi will present new haemophilia data with seven scientific abstracts, including one oral presentation highlighting three years of treatment with Altuvoct from the XTEND-ed study.</description>
</item>
<item>
<title>Sobi Receives European Commission Approval for Aspaveli® (pegcetacoplan) for the Treatment of C3G and Primary IC-MPGN</title>
<link>https://6ix.com/company/swedish-orphan-biovitrum-ab-publ/news/sobi-receives-european-commission-approval-for-aspavelir-pegcetacoplan-for-the-treatment-of-c3g-and-primary-ic-mpgn</link>
<guid isPermaLink="true">https://6ix.com/company/swedish-orphan-biovitrum-ab-publ/news/sobi-receives-european-commission-approval-for-aspavelir-pegcetacoplan-for-the-treatment-of-c3g-and-primary-ic-mpgn</guid>
<pubDate>Fri, 16 Jan 2026 11:49:00 GMT</pubDate>
<description>Sobi® (STO: SOBI), today announced that the European Commission (EC) has approved Aspaveli® (pegcetacoplan) for the treatment of adult and adolescent patients aged 12 to 17 years with C3 glomerulopathy (C3G) or primary immune-complex membranoproliferative glomerulonephritis (IC-MPGN) in combination with a renin-angiotensin system (RAS) inhibitor, unless RAS inhibitor treatment is not tolerated or contraindicated</description>
</item>
<item>
<title>Sobi's 2025 annual revenue and adjusted EBITA margin exceed previous outlook</title>
<link>https://6ix.com/company/swedish-orphan-biovitrum-ab-publ/news/sobis-2025-annual-revenue-and-adjusted-ebita-margin-exceed-previous-outlook</link>
<guid isPermaLink="true">https://6ix.com/company/swedish-orphan-biovitrum-ab-publ/news/sobis-2025-annual-revenue-and-adjusted-ebita-margin-exceed-previous-outlook</guid>
<pubDate>Thu, 15 Jan 2026 12:13:00 GMT</pubDate>
<description>Swedish Orphan Biovitrum AB (publ) (Sobi®) (STO: SOBI) announces today that revenue and adjusted EBITA margin for the full year 2025 were higher than previous outlook. Full-year revenue was approximately SEK 28.2 B, representing approximately 15 per cent growth at constant exchange rate (CER)[1]. Adjusted EBITA margin1,[2] was approximately 40 per cent of revenues.</description>
</item>
<item>
<title>Invitation: Sobi's Q4 and FY 2025 report</title>
<link>https://6ix.com/company/swedish-orphan-biovitrum-ab-publ/news/invitation-sobis-q4-and-fy-2025-report</link>
<guid isPermaLink="true">https://6ix.com/company/swedish-orphan-biovitrum-ab-publ/news/invitation-sobis-q4-and-fy-2025-report</guid>
<pubDate>Wed, 14 Jan 2026 10:10:00 GMT</pubDate>
<description>Sobi plans to publish its report for the fourth quarter and full year of 2025 on 5 February 2026 at 08:00 CET.</description>
</item>
<item>
<title>Sobi to advance Gamifant® (emapalumab) in interferon-gamma-driven sepsis (IDS) based on EMBRACE topline data</title>
<link>https://6ix.com/company/swedish-orphan-biovitrum-ab-publ/news/sobi-to-advance-gamifantr-emapalumab-in-interferon-gamma-driven-sepsis-ids-based-on-embrace-topline-data</link>
<guid isPermaLink="true">https://6ix.com/company/swedish-orphan-biovitrum-ab-publ/news/sobi-to-advance-gamifantr-emapalumab-in-interferon-gamma-driven-sepsis-ids-based-on-embrace-topline-data</guid>
<pubDate>Wed, 07 Jan 2026 18:01:00 GMT</pubDate>
<description>Sobi® (STO: SOBI) today announced that topline results from the Phase 2a EMBRACE study evaluating Gamifant® (emapalumab) for interferon-gamma (IFNγ)-driven sepsis (IDS), showed proof-of-concept with observed improvement in organ dysfunction and survival.</description>
</item>
<item>
<title>Save the Date: Sobi to host a Capital Markets Day on 18 February 2026</title>
<link>https://6ix.com/company/swedish-orphan-biovitrum-ab-publ/news/save-the-date-sobi-to-host-a-capital-markets-day-on-18-february-2026</link>
<guid isPermaLink="true">https://6ix.com/company/swedish-orphan-biovitrum-ab-publ/news/save-the-date-sobi-to-host-a-capital-markets-day-on-18-february-2026</guid>
<pubDate>Thu, 18 Dec 2025 10:20:00 GMT</pubDate>
<description>Swedish Orphan Biovitrum AB (Sobi) invites investors, analysts, and other stakeholders to its upcoming Capital Markets Day (CMD), which will be held in person in Stockholm, Sweden, on 18 February 2026, starting at 13:00 CET. A live webcast will also be available for remote participants.</description>
</item>
<item>
<title>Sobi to acquire Arthrosi Therapeutics, strengthening pipeline for the potential treatment of gout</title>
<link>https://6ix.com/company/swedish-orphan-biovitrum-ab-publ/news/sobi-to-acquire-arthrosi-therapeutics-strengthening-pipeline-for-the-potential-treatment-of-gout</link>
<guid isPermaLink="true">https://6ix.com/company/swedish-orphan-biovitrum-ab-publ/news/sobi-to-acquire-arthrosi-therapeutics-strengthening-pipeline-for-the-potential-treatment-of-gout</guid>
<pubDate>Mon, 15 Dec 2025 13:00:00 GMT</pubDate>
<description>Arthrosi Therapeutics, Inc., (Arthrosi) has entered into a definitive agreement to be acquired by Sobi® (STO:SOBI). The acquisition strengthens Sobi's gout franchise by adding pozdeutinurad (AR882), an investigational next-generation, once-daily oral URAT1 inhibitor currently being evaluated in two fully recruited global Phase 3 clinical studies for the potential management of progressive and tophaceous gout and expected to read out in 2026. Pozdeutinurad complements Sobi's pipeline by adding a</description>
</item>
<item>
<title>Viva Biotech's invested and incubated company, Arthrosi, has entered into an acquisition agreement with Sobi for a total transaction value of up to US$1.5 billion.</title>
<link>https://6ix.com/company/swedish-orphan-biovitrum-ab-publ/news/viva-biotechs-invested-and-incubated-company-arthrosi-has-entered-into-an-acquisition-agreement-with-sobi-for-a-total-transaction-value-of-up-to-usdollar15-billion-1</link>
<guid isPermaLink="true">https://6ix.com/company/swedish-orphan-biovitrum-ab-publ/news/viva-biotechs-invested-and-incubated-company-arthrosi-has-entered-into-an-acquisition-agreement-with-sobi-for-a-total-transaction-value-of-up-to-usdollar15-billion-1</guid>
<pubDate>Mon, 15 Dec 2025 06:06:00 GMT</pubDate>
<description>Swedish Orphan Biovitrum AB (STO: SOBI) recently announced that it has entered into an acquisition agreement with Arthrosi Therapeutics, Inc., which was invested in and incubated by Viva Biotech Holdings. Under the terms of the agreement, Sobi will pay up to US$1.5 billion in total transaction value, including an upfront payment at closing of US$950 million, subject to customary adjustments, and contingent consideration of up to US$550 million. The transaction is expected to close in the first h</description>
</item>
<item>
<title>Sobi Receives Positive CHMP Opinion for Aspaveli® (pegcetacoplan) for the Treatment of C3G and Primary IC-MPGN</title>
<link>https://6ix.com/company/swedish-orphan-biovitrum-ab-publ/news/sobi-receives-positive-chmp-opinion-for-aspavelir-pegcetacoplan-for-the-treatment-of-c3g-and-primary-ic-mpgn</link>
<guid isPermaLink="true">https://6ix.com/company/swedish-orphan-biovitrum-ab-publ/news/sobi-receives-positive-chmp-opinion-for-aspavelir-pegcetacoplan-for-the-treatment-of-c3g-and-primary-ic-mpgn</guid>
<pubDate>Fri, 12 Dec 2025 13:12:00 GMT</pubDate>
<description>Sobi® (STO: SOBI) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has adopted a positive opinion recommending the marketing authorisation of Aspaveli® (pegcetacoplan) for the treatment of adult and adolescent patients with C3 glomerulopathy (C3G) or primary immune-complex membranoproliferative glomerulonephritis (IC-MPGN).</description>
</item>
<item>
<title>Sobi to Showcase Scientific advances and Commitment to Haematology at ASH 2025</title>
<link>https://6ix.com/company/swedish-orphan-biovitrum-ab-publ/news/sobi-to-showcase-scientific-advances-and-commitment-to-haematology-at-ash-2025</link>
<guid isPermaLink="true">https://6ix.com/company/swedish-orphan-biovitrum-ab-publ/news/sobi-to-showcase-scientific-advances-and-commitment-to-haematology-at-ash-2025</guid>
<pubDate>Fri, 05 Dec 2025 17:46:00 GMT</pubDate>
<description>Sobi® (STO: SOBI), today announced its participation at the 65th American Society of Hematology (ASH) Annual Meeting, taking place on 6 – 9 December in Orlando, Florida. At this year's meeting, Sobi will showcase its commitment to advancing care in haematology with 19 scientific abstracts, including two oral presentations. These feature the most recent clinical data and insights from completed and ongoing studies across Sobi's innovative portfolio including data from efanesoctocog alfa, pegcetac</description>
</item>
<item>
<title>The New England Journal of Medicine Publishes Positive Phase 3 VALIANT Results of pegcetacoplan for C3G and Primary IC-MPGN</title>
<link>https://6ix.com/company/swedish-orphan-biovitrum-ab-publ/news/the-new-england-journal-of-medicine-publishes-positive-phase-3-valiant-results-of-pegcetacoplan-for-c3g-and-primary-ic-mpgn</link>
<guid isPermaLink="true">https://6ix.com/company/swedish-orphan-biovitrum-ab-publ/news/the-new-england-journal-of-medicine-publishes-positive-phase-3-valiant-results-of-pegcetacoplan-for-c3g-and-primary-ic-mpgn</guid>
<pubDate>Thu, 04 Dec 2025 07:39:00 GMT</pubDate>
<description>Sobi® (STO:SOBI) today announced that The New England Journal of Medicine (NEJM) published positive results from the Phase 3 VALIANT study investigating pegcetacoplan for C3 glomerulopathy (C3G) and primary immune complex membranoproliferative glomerulonephritis (IC-MPGN), which are severe and rare kidney diseases.</description>
</item>
<item>
<title>Clinically meaningful pivotal study results for olezarsen in sHTG presented as a late breaker at AHA Scientific Sessions</title>
<link>https://6ix.com/company/swedish-orphan-biovitrum-ab-publ/news/clinically-meaningful-pivotal-study-results-for-olezarsen-in-shtg-presented-as-a-late-breaker-at-aha-scientific-sessions</link>
<guid isPermaLink="true">https://6ix.com/company/swedish-orphan-biovitrum-ab-publ/news/clinically-meaningful-pivotal-study-results-for-olezarsen-in-shtg-presented-as-a-late-breaker-at-aha-scientific-sessions</guid>
<pubDate>Sat, 08 Nov 2025 15:40:00 GMT</pubDate>
<description>Sobi® (STO: SOBI) today announced that, the TIMI Study Group today has presented positive results from the pivotal Phase 3 CORE and CORE2 studies of olezarsen in people with severe hypertriglyceridemia (sHTG) at the American Heart Association 2025 Scientific Sessions. The studies met the primary endpoint, with olezarsen achieving a highly statistically significant placebo-adjusted mean reduction in fasting triglyceride (TG) levels of up to 72% at six months. The reductions were sustained through</description>
</item>
<item>
<title>Sobi to present New One-Year Data on pegcetacoplan's efficacy in C3G and primary IC-MPGN and new outcome data on NASP at ASN Kidney Week</title>
<link>https://6ix.com/company/swedish-orphan-biovitrum-ab-publ/news/sobi-to-present-new-one-year-data-on-pegcetacoplans-efficacy-in-c3g-and-primary-ic-mpgn-and-new-outcome-data-on-nasp-at-asn-kidney-week</link>
<guid isPermaLink="true">https://6ix.com/company/swedish-orphan-biovitrum-ab-publ/news/sobi-to-present-new-one-year-data-on-pegcetacoplans-efficacy-in-c3g-and-primary-ic-mpgn-and-new-outcome-data-on-nasp-at-asn-kidney-week</guid>
<pubDate>Wed, 05 Nov 2025 16:36:00 GMT</pubDate>
<description>Sobi® (STO: SOBI) today announced that data on Aspaveli/Empaveli in C3 glomerulopathy (C3G) and primary immune complex membranoproliferative glomerulonephritis (IC-MPGN) and NASP in uncontrolled gout will be presented at ASN Kidney Week 2025, 5-9 November in Houston, Texas. In total, the company will be present 1 oral and 6 poster presentations for Aspaveli/Empaveli, as well as 3 poster presentations for NASP.</description>
</item>
</channel>
</rss>